mao-b-in-5

MAO-B-IN-5 is a potent, selective, and orally active MAO-B inhibitor with an IC50 of 0.204 μM, showing potential for research in Parkinson's disease (PD) [1].

AChE/BChE/MAO-B-IN-5 is a multi-target inhibitor capable of crossing the blood-brain barrier, targeting cholinesterases (AChE and BChE) and monoamine oxidase MAO-B. It exhibits IC50 values of 0.24 µM for AChE, 6.29 µM for BChE, and 0.11 µM for MAO-B. AChE/BChE/MAO-B-IN-5 holds potential for research in neurodegenerative diseases such as Alzheimer's disease.

AChE/MAO-B-IN-5 is a dual inhibitor of AChE and MAO-B. It is utilized in the investigation of Alzheimer's disease.

MAO-B-IN-51 (Compound 8f) is an orally active and selective MAO-B inhibitor that can cross the blood-brain barrier, with an IC50 value of 48.9 nM (MDS). It is known to enhance long-term memory.

MAO-B-IN-50 (Compound C20) is a selective MAO-B inhibitor with an IC50 value of 0.06 μM. It effectively inhibits the aggregation of Aβ40/42 and Tau proteins, with an overall IC50 of approximately 1 μM. Additionally, MAO-B-IN-50 exhibits potent and selective AChE inhibitory activity (IC50 = 1.78 μM). This compound is useful in Alzheimer's disease research.

hMAO-B-IN-5 is a potent reversible and selective human monoamine oxidase hMAO-B inhibitor (IC50:0.12μM). hMAO-B-IN-5 can cross the blood-brain barrier and can be used in the study of Parkinson's disease. It is a promising compound in the treatment and diagnosis of central nervous system diseases.

Femoxetine is a 5-HT inhibitor with antidepressant activity that potentiates morphine-induced anti-injury feelings and inhibits MAO-A and MAO-B required for the production of high exercise capacity in mice.

HDAC6-IN-49 (Compound 3) is an inhibitor of HDAC, with IC50 values of 0.012 and 0.735 µM against HDAC6 and HDAC1, respectively. Additionally, it inhibits MAO-B, cholinesterase (ChE), histamine receptor (H3R), and serotonin 6 receptor (5-HT6R). HDAC6-IN-49 exhibits neuroprotective effects in SH-SY5Y cells and enhances cognitive functions and motor abilities in fruit fly models of Parkinson's disease and C. elegans models of Alzheimer's disease.

PZ-1922 free base is a brain-penetrant 5-HT6R/5-HT3R antagonist with Ki values of 17 nM and 0.45 nM, respectively. It reversibly inhibits MAO-B (pIC50: 8.93). In rat novel object recognition (NOR) tests, PZ-1922 free base counteracts Scopolamine (SCOP)-induced memory deficits and prevents Aβ-induced memory decline in T-maze tests.

MAO-A/B-IN-5 is an orally active inhibitor of MAO-A (IC50 = 73.88 μM) and MAO-B (IC50 = 91.08 μM). It reverses sodium nitroprusside (SNP)-induced brain lipid peroxidation (IC50 = 130.2 μM) and protein carbonylation (IC50 = 229.8 μM). In mice, MAO-A/B-IN-5 exhibits dose-dependent and time-dependent antidepressant-like effects. This compound is applicable in depression research.

Multitarget AD-IN-5 (Compound 20), a derivative of 9-Aminoacridine, is a neuroprotective agent. It exhibits IC50 values of 0.614 μM for hAChE, 0.448 μM for hBChE, 3.73 μM for MAO-A, and 1.55 μM for hMAO-B. This compound can reduce both the length and diameter of Aβ42 fibrils and decrease the number of fibrils per unit area. The CC50 value for SH-SY5Y cells is 95 μM. Multitarget AD-IN-5 is applicable in Alzheimer's disease research.

Harmane (Loturine) is a bio-active β-Carboline and monoamine oxidase inhibitor found in coffee and tobacco smoke.

Rasagiline-13C3 (mesylate) is intended for use as an internal standard for the quantification of rasagiline by GC- or LC-MS. Rasagiline (mesylate) (T6962) is an inhibitor of monoamine oxidase B (MAO-B; IC50= 4.43 nM for the rat brain enzyme).1It is selective for MAO-B over MAO-A (IC50= 412 nM for the rat brain enzyme). It inhibits serum and NGF withdrawal-induced apoptosis of PC12 cells when used at concentrations ranging from 0.01 to 100 μM.2Rasagiline inhibits rat brain MAO-Bin vivo (ED50= 0.1 mg/kg).1It reduces cerebral edema in a mouse model of traumatic brain injury.2Rasagiline (0.1 mg/kg) reduces cortical and hippocampal levels of full-length and soluble amyloid precursor protein (APP) in rats and mice. It also reduces α-synuclein-induced substantia nigral neuron loss and improves motor dysfunction in a mouse model of Parkinson's disease.3Formulations containing rasagiline have been used in the treatment of Parkinson's disease.

Dual AChE-MAO B-IN-5, an indanone derivative, serves as an effective dual inhibitor for AChE and MAO-B, displaying IC50 values of 0.0224 μM for AChE, 0.0412 μM for MAO-B, and 0.1116 μM for MAO-A. Additionally, it exhibits antioxidant properties and inhibits β-amyloid plaque aggregation, making it suitable for Alzheimer's disease (AD) research.

MAO-B-IN-3 is a selective, reversible inhibitor of monoamine oxidase B (MAO-B) with an IC50 of 96 nM and shows affinity for the 5-HT6 receptor with a Ki of 696 nM, making it suitable for Alzheimer's disease research [1].

MAO-IN-3 (Compound 5), a reversible and competitive monoamine oxidase (MAO) inhibitor with inhibition constants (K i) of 0.6 μM for MAO A and 0.2 μM for MAO B, effectively suppresses LN-229 glioblastoma cell proliferation, as denoted by an inhibitory concentration (IC50) of 0.8 μM. This compound holds potential application in cancer research [1].

PZ-1922 (Compound 16), able to cross the blood-brain barrier, is a dual antagonist for 5-HT6R and 5-HT3R with K i values of 17 nM and 0.45 nM, respectively. It also reversibly inhibits MAO-B with a pIC50 of 8.93. Moreover, PZ-1922 mitigates scopolamine (SCOP)-induced memory deficits in rats as observed in the novel object recognition (NOR) test and hinders Aβ-induced memory impairment in the T-maze test [1].

Harmane (Standard) is a reference standard for research and analysis in studies involving Harmane. Harmane (Loturine) is a bio-active β-Carboline and monoamine oxidase inhibitor found in coffee and tobacco smoke.